Login with Linked

Follow us on

Link Linkedin Youtube

Ojjaara

Ojjaara is an oral medication for adults with intermediate or high-risk myelofibrosis and anemia. It targets JAK1, JAK2, and ACVR1 to reduce spleen size, relieve symptoms, and improve anemia.

Molecule Details :

  • Molecule Name :

    Momelotinib

  • Innovator :

    GLAXOSMITHKLINE LLC

  • Approval Date :

    15-Sep-23

  • NCE-1 Date :

    15-Sep-27

  • NCE Date :

    15-Sep-28

  • Dosage Form :

    Tablet

  • Strength :

    100mg, 150mg and 200mg

  • Therapeutic Category :

    Anticancer

  • Revenue ($M) :

    451

Year-wise Projected Sales ($M) :

  • 2025 :

    804

  • 2026 :

    1,063

  • 2027 :

    1,251

  • 2028 :

    1,430

  • 2029 :

    1,585

  • 2030 :

    1,730

  • 2031 :

    1,718
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.
Request a Quote

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Schedule a Call With Us
Login with Linked

Follow us on

Linkedin Youtube Link

Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?

Not Now
Logout
Need your comparator insight?